GlassScriptPhysician profile
Jordan Pharris
NPI 1659934917
$920.47
in general payments reported to CMS, 2019-2025
20 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $32.92 · 2023: $451 · 2024: $227 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $887.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $110.86 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $106.58 | 2023-2025 | |
| Glaxosmithkline, LLC. | $100.02 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $94.51 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $85.56 | 2023-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $76.38 | 2022-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $63.54 | 2022-2024 | |
| Mylan Specialty L.P. | $49.24 | 2023-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $44.37 | 2023-2024 | Verquvo, Belsomra, Gardasil 9 |
| Amgen INC. | $29.00 | 2023-2024 | Evenity, Prolia, Otezla |
| Becton, Dickinson and Company | $22.46 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $17.60 | 2023 | Nuedexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.47 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $16.34 | 2024 | Xarelto |
| Neurelis, INC. | $15.59 | 2023 | Valtoco |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $15.43 | 2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $14.99 | 2023 | Gvoke Hypopen |
| Nestle Healthcare Nutrition INC. | $14.52 | 2023 | |
| Lilly USA, LLC | $14.25 | 2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.76 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Pharris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.